1. Home
  2. PD vs VRDN Comparison

PD vs VRDN Comparison

Compare PD & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PagerDuty Inc.

PD

PagerDuty Inc.

N/A

Current Price

$6.52

Market Cap

636.9M

Sector

Technology

ML Signal

N/A

Logo Viridian Therapeutics Inc.

VRDN

Viridian Therapeutics Inc.

N/A

Current Price

$27.24

Market Cap

2.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PD
VRDN
Founded
2009
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
636.9M
2.7B
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
PD
VRDN
Price
$6.52
$27.24
Analyst Decision
Buy
Strong Buy
Analyst Count
9
13
Target Price
$12.63
$40.92
AVG Volume (30 Days)
3.3M
973.9K
Earning Date
03-12-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
416.95
N/A
EPS
1.87
N/A
Revenue
$492,546,000.00
$5,706,000.00
Revenue This Year
$3.58
$27.65
Revenue Next Year
$1.65
$253.29
P/E Ratio
$3.70
N/A
Revenue Growth
5.36
N/A
52 Week Low
$6.15
$9.90
52 Week High
$19.70
$34.29

Technical Indicators

Market Signals
Indicator
PD
VRDN
Relative Strength Index (RSI) 32.18 40.54
Support Level $6.17 $26.31
Resistance Level $16.45 $33.71
Average True Range (ATR) 0.42 1.14
MACD 0.05 -0.10
Stochastic Oscillator 20.21 23.59

Price Performance

Historical Comparison
PD
VRDN

About PD PagerDuty Inc.

PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Share on Social Networks: